文献速递消化道肿瘤放疗放疗物理与技术

局部晚期直肠癌化疗联合或不联合放疗后第二恶性肿瘤的发生

Development of Second Malignancies Following Chemotherapy With or Without Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-07-19

本研究纳入2624例II-III期局部晚期直肠癌患者,比较化疗(460例)与同步放化疗(2164例)后第二盆腔恶性肿瘤(SPM)及第二非盆腔恶性肿瘤(SNPM)的累积发生率。

要点

  • 同步放化疗组第二非盆腔恶性肿瘤10年累积发生率显著高于单纯化疗组(11.0% vs 4.4%)。
  • 年龄>50岁、糖尿病和吸烟与第二非盆腔恶性肿瘤风险升高相关。

核心结论

  • 局部晚期直肠癌患者接受同步放化疗后第二盆腔恶性肿瘤累积发生率与单纯化疗相比无显著差异。
  • 同步放化疗组第二非盆腔恶性肿瘤累积发生率显著高于单纯化疗组。

研究设计与样本

  • 回顾性队列研究,纳入2624例II-III期局部晚期直肠癌患者,其中460例接受化疗,2164例接受同步放化疗。
  • 采用2年里程碑分析,以死亡为竞争风险计算第二恶性肿瘤累积发生率。
  • 两组中位随访时间均为6年。

主要发现

  • 化疗组诊断7例第二盆腔恶性肿瘤,同步放化疗组诊断68例。
  • 75例第二盆腔恶性肿瘤中72例为泌尿生殖系统癌症,仅3例为肉瘤。
  • 同步放化疗组第二非盆腔恶性肿瘤10年累积发生率显著高于化疗组(11.0% vs 4.4%)。

临床怎么用

  • 对于局部晚期直肠癌患者,同步放化疗未显著增加第二盆腔恶性肿瘤风险,但需关注第二非盆腔恶性肿瘤风险升高。
  • 年龄>50岁、糖尿病和吸烟患者应加强第二非盆腔恶性肿瘤的监测与预防。
  • 采用调强放疗可能有助于降低第二盆腔恶性肿瘤风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to identify factors associated with second pelvic malignancies (SPM), as well as second nonpelvic malignancies (SNPM), after chemotherapy with or without radiation therapy (RT) for locally advanced rectal cancer (LARC). METHODS AND MATERIALS: Patients diagnosed with stage II-III LARC. Cumulative incidence of second malignancies was analyzed using a 2-year landmark analysis with death as a competing risk. RESULTS: Among 2624 patients with LARC, 460 received chemotherapy and 2164 received RT with concurrent chemotherapy (CXRT). With a median follow-up of 6 years in both cohorts, 7 SPMs were diagnosed in the chemotherapy cohort and 68 SPMs were diagnosed in the CXRT cohort. The 5- and 10-year cumulative incidence of SPM in the chemotherapy cohort were 2.3% and 4.2%, respectively, compared with 2.1% and 5.8% in the CXRT cohort (P = .3). Older age (>50) was significantly associated with development of SPM on multivariable analysis (hazard ratio [HR], 3.03; P = .005). Intensity-modulated RT was associated with reduced risk of SPM compared with conventional RT (P = .014). Of the total 75 SPMs, 72 were genitourinary cancers and only 3 were sarcomas. For SNPM, the 10-year cumulative incidence was significantly higher in the CXRT group compared with the chemotherapy group (11.0% vs 4.4%). Older age (>50) was associated with increased risk of SNPM (HR, 2.48; P < .001). Diabetes was associated with more SNPM (HR, 1.51; P = .028), whereas abstaining from tobacco was associated with decreased risk of SNPM (HR 0.63, P = .013). CONCLUSION: The CI of SPM was not significantly higher in patients who received CXRT compared with chemotherapy alone for LARC. SNPM CI was increased in the CXRT compared with chemotherapy-alone cohort, and higher in smokers, diabetics, and patients >50 years.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Tringale KR, Patel KH, Hilal L, et al. Development of Second Malignancies Following Chemotherapy With or Without Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 40691994. doi:10.1016/j.ijrobp.2025.07.1424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。